患者在 EGFR-TKI 获得性耐药后接受培美曲塞再挑战的反应。
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
机构信息
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, People's Republic of China.
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, People's Republic of China.
出版信息
Lung Cancer. 2014 May;84(2):203-5. doi: 10.1016/j.lungcan.2014.02.010. Epub 2014 Feb 28.
Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib.
表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）获得性耐药已成为一个重要的临床问题，尽管吉非替尼、厄洛替尼和阿法替尼等 EGFR-TKI 已使具有 EGFR 突变的晚期非小细胞肺癌（NSCLC）患者的无进展生存期达到 8-14 个月[1,2]。我们在此报告一例晚期肺腺癌患者，该患者在厄洛替尼获得性耐药后，培美曲塞再次治疗有效。
Zotero 插件